![Biotechnology / Immunosuppressants / Monoclonal antibodies / Cytokines / Tumor necrosis factor-alpha / TNF inhibitor / Certolizumab pegol / Clinical trial / Pharmacology / Medicine / Biology Biotechnology / Immunosuppressants / Monoclonal antibodies / Cytokines / Tumor necrosis factor-alpha / TNF inhibitor / Certolizumab pegol / Clinical trial / Pharmacology / Medicine / Biology](https://www.pdfsearch.io/img/6c1e9d05213bd49922a43095b6b113ef.jpg)
| Document Date: 2014-04-28 15:04:32 Open Document File Size: 357,11 KBShare Result on Facebook
City La Jolla / / Continent Europe / / IndustryTerm 2a protocol / cross / / MedicalCondition active disease / IBD / Clinical sepsis / bacteremia / strain / inflammation / bacteremia/sepsis / Severe Active Ulcerative Colitis / systemic opportunistic infections / different colitis / / MedicalTreatment Surgery / / Organization FDA / National Institute of Health / Recombinant DNA Advisory Committee / / Person Pieter Rottiers / W. Sandborn / William J. Sandborn / B. Coulie / L. Steidler / Lothar Steidler / Bernard Coulie / P. Rottiers / / Position Vice President R&D / CEO / PhD Vice President / PhD Vice President Technology / / Product Prednisone / Current capsule / Concomitant medication / / Technology alpha / Phase 2a protocol / Recombinant DNA / / URL www.clinicaltrialsregister.eu / www.clinicaltrials.gov / /
SocialTag |